# A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

> **NCT07029399** · PHASE1 · RECRUITING · sponsor: **NiKang Therapeutics, Inc.** · enrollment: 205 (estimated)

## Conditions studied

- HR+ Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- CCNE1 Amplified Advanced Solid Tumors
- HR+ HER2- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Uterine Carcinosarcoma

## Interventions

- **DRUG:** NKT5097 CDK2/CDK4 dual degrader

## Key facts

- **NCT ID:** NCT07029399
- **Lead sponsor:** NiKang Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 205 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07029399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07029399, "A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07029399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*